Some cases of the most common childhood cancer, B-cell acute lymphoblastic leukemia (B-ALL), return after treatment—and genetic changes present from the start may help explain why. Scientists at St. Jude Children's Research ...
Nov 2, 2026
0
4
Researchers from Newcastle University and Great Ormond Street Hospital have identified new predictors of relapse in children and young people with acute lymphoblastic leukemia (ALL) treated with the immunotherapy drug blinatumomab, ...
Oct 21, 2026
0
7
Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival ...
Jul 7, 2026
0
7
Researchers have introduced a novel diagnostics method that can more sensitively detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL), the most common type of pediatric cancer, compared to other publicly available ...
May 14, 2026
0
5
Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukemia cells may also harm the body's ability to make new, healthy blood ...
May 12, 2026
0
18
B-cell acute lymphoblastic leukemia is the most common form of childhood cancer. In this type of cancer, which affects blood cells, one of the most common abnormalities is the presence of cells with an excess of chromosomes ...
Apr 8, 2026
0
8
Despite a host of checks and balances that usually prevent harmful genetic mutations, sometimes mistakes happen, with serious consequences. Now, researchers from Japan elucidate how a common mutation underlying a common childhood ...
Mar 25, 2026
0
4
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning ...
Dec 8, 2025
0
7
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat ...
Oct 20, 2025
0
11
Chinese researchers have developed a novel method to efficiently engineer natural killer (NK) cells for cancer immunotherapy. NK cells are central to early antiviral and anticancer defense—among other immune system roles—making ...
Oct 10, 2025
0
77
